Ravulizumab

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 432 publications

Ravulizumab administration for relapse prevention in atypical hemolytic uremic syndrome with a CFH variant: A case report.

Ravulizumab administration for relapse prevention in atypical hemolytic uremic syndrome with a CFH variant: A case report.

Journal: Internal medicine (Tokyo, Japan)
Published: June 10, 2026

Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.

Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.

Journal: Expert review of clinical pharmacology
Published: May 29, 2026

Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?

Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: May 25, 2026

Infection risk mitigation with complement inhibitors in kidney disease.

Infection risk mitigation with complement inhibitors in kidney disease.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: May 23, 2026

Nipocalimab (Imaavy) for myasthenia gravis.

Nipocalimab (Imaavy) for myasthenia gravis.

Journal: The Medical letter on drugs and therapeutics
Published: May 15, 2026

Ravulizumab in pregnancy: the case for cautious optimism.

Ravulizumab in pregnancy: the case for cautious optimism.

Journal: Blood advances
Published: May 01, 2026

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome With Kidney Recovery Despite Delayed Initiation of Complement Blockade.

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome With Kidney Recovery Despite Delayed Initiation of Complement Blockade.

Journal: Cureus
Published: April 30, 2026

Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.

Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.

Journal: Journal of clinical medicine
Published: March 26, 2026

Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany.

Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany.

Journal: Neurological research and practice
Published: March 24, 2026

Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab".

Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab".

Journal: Annals of clinical and translational neurology
Published: March 17, 2026

Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis.

Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis.

Journal: Journal of neuroimmunology
Published: March 15, 2026

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 05, 2026
Showing 1-12 of 432

Last Updated: 06/30/2026